Shattuck Labs Shares Spike 38.7% on High Volume after 8-K Filing and Ono Pharma Deal
By ATTN Desk · Editorial oversight: Sean Han
Introduction
SHATTUCK LABS INC (NASDAQ: STTK) is a clinical-stage biotechnology company focused on engineering biologic medicines targeting tumor necrosis factor (TNF) receptors. The company operates from its headquarters in Austin, Texas, and has additional operations in Durham, North Carolina. Shattuck Labs specializes in antibody and bifunctional fusion-protein therapeutics designed to address inflammatory bowel disease (IBD), autoimmune conditions, and cancer.
Corporate Structure
Founded in 2016, Shattuck Labs employs between 51 and 200 professionals across research, protein engineering, clinical development, and corporate functions. Its leadership team includes:
- Taylor Schreiber, M.D., Ph.D., Chief Executive Officer and Co-Founder, oversees corporate strategy and clinical development programs.
- George Golumbeski, Ph.D., Chairman of the Board, previously served as Executive Vice President of Business Development at Celgene, and guides strategic collaborations.
- Helen M. Boudreau, MBA, Chief Financial Officer, has held senior finance roles at the Bill & Melinda Gates Medical Research Institute, Novartis, and Pfizer.
- Carrie Brownstein, M.D., a board member with experience in oncology R&D and global regulatory affairs.
- Neil Gibson, Ph.D., Chief Scientific Officer (Biologics) at COI Pharma, directs protein engineering initiatives.
Biotechnology by Sangharsh Lohakare
Developments and News
- On February 13, 2024, Shattuck entered a collaboration and option agreement with Ono Pharmaceutical Co., Ltd. Under this agreement, Shattuck will generate bifunctional fusion proteins utilizing its proprietary technology. The potential revenue from this agreement could reach $227 million in milestones and royalties.
- In its July 16, 2025 Schedule 13G/A filing, BlackRock, Inc. disclosed beneficial ownership of 878,754 common shares, representing 1.80% of the outstanding stock.
- On July 29, 2025, The Vanguard Group reported beneficial ownership of 2,148,174 shares, which constitutes 4.48% of the company, with sole dispositive power over 2,133,317 shares.
- On August 5, 2025, Shattuck Labs filed a Current Report on Form 8-K disclosing material agreements, financing arrangements, and corporate events under Items 1.01, 3.02, 7.01, and 9.01.
- The company plans to file an Investigational New Drug (IND) application for its lead program, SL-325, in the third quarter of 2025.
Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Share Price (August 5, 2025) | $1.03 |
| Daily Change | +38.68% |
| Volume | 10,292,245 |
| 52-Week Range | $0.6920 – $3.9500 |
| Market Cap | $35.58 million |
| Revenue (TTM) | $4.61 million |
| Net Income (TTM) | –$70.61 million |
| EPS (TTM) | –$1.39 |
| Total Cash (MRQ) | $60.9 million |
| Total Debt/Equity (MRQ) | 4.72% |
| Price/Sales (TTM) | 8.20 |
| Price/Book (MRQ) | 0.53 |
| Beta (5 Y Monthly) | 1.64 |
The stock’s trading volume exceeded 10 million on August 5, significantly higher than its average volume of 231,735 shares. Shattuck’s balance sheet indicates $60.9 million in cash with a modest debt level, while the company reports persistent net losses due to ongoing research and development and pre-commercialization expenses. The SL-325 program—a first-in-class DR3 antagonist antibody—targets the clinically validated TL1A/DR3 pathway related to IBD and various autoimmune disorders. The collaboration with Ono Pharmaceutical is intended to extend Shattuck’s pipeline of bifunctional fusion proteins.
Market Position and Industry Context
Shattuck Labs operates within the competitive biotechnology research sector, specializing in TNF receptor modulators. These therapies have demonstrated clinical utility in managing autoimmune and inflammatory diseases. Shattuck aims to differentiate through deeper and more durable receptor blockade. Its Agonist Redirected Checkpoint (ARC®) platform further broadens potential applications in oncology. The company’s market capitalization reflects its pre-revenue, clinical-stage status, with significant institutional investment from firms like Vanguard and BlackRock indicating a long-term confidence in its business strategy.
tl;dr
On August 5, 2025, SHATTUCK LABS INC filed an 8-K disclosing material agreements and financing developments. The stock rose 38.68% to $1.03 on high trading volume. Institutional filings on July 16 and July 29 revealed BlackRock’s 1.80% stake and Vanguard’s 4.48% stake. Shattuck plans to submit its IND application for SL-325—a first-in-class DR3 antagonist—in Q3 2025 and continues its collaboration with Ono Pharmaceutical on bifunctional fusion proteins. Future milestones include IND clearance and early clinical data readouts.